American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab Maintenance in Relapsed/Refractory CLL

ASH 2023 - CLL

Results of the phase 2 CLL2-BZAG trial indicated that MRD-guided triple combination of zanubrutinib, venetoclax, and obinutuzumab induced deep remissions in patients with R/R CLL including those previously treated with BTKi and/or venetoclax. Read More ›

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with R/R CLL Previously Treated with Fixed-Dose Venetoclax/Rituximab

ASH 2023 - CLL

Final data from the phase 3 MURANO trial demonstrated a significantly prolonged time to second progression-free survival event in the venetoclax/rituximab arm, with high response rates achieved even by patients who subsequently received retreatment or crossed over to venetoclax-based regimens or BTKi therapy. Read More ›

PFS Benefit with Zanubrutinib Over Bendamustine/Rituximab Across Multiple High-Risk Factors in the Phase 3 SEQUOIA Study in Patients with Treatment-Naive CLL/SLL without del(17p)

ASH 2023 - CLL

Biomarker subgroup analysis results indicate that zanubrutinib treatment was associated with superior PFS in all biomarker subgroups analyzed compared to bendamustine/rituximab in treatment-naïve patients with CLL/SLL without del(17p). Read More ›

Updated Results of the Phase 1b BRUIN Study of Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory CLL

ASH 2023 - CLL

Results of the phase 1/2 BRUIN study indicate that fixed-duration pirtobrutinib combined with venetoclax ± rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia. Read More ›

Phase 2 Study Results of the Novel TL-895 BTK Inhibitor in Treatment-Naïve and Relapsed/Refractory CLL/SLL

ASH 2023 - CLL

Results of a phase 2 study suggests that the highly selective Bruton tyrosine kinase inhibitor TL-895 therapy led to rapid bone marrow clearance of leukemic cells to induce deeper and more durable responses, with a favorable adverse event profile in patients with treatment-naïve and relapsed/refractory CLL/SLL. Read More ›

Longer Follow-up Results of ELEVATE-TN trial of Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Patients with Treatment-Naive CLL

ASH 2023 - CLL

Extended follow-up results of the ELEVATE-TN trial (median follow-up of 74.5 months) confirmed sustained efficacy and safety of acalabrutinib/obinutuzumab and acalabrutinib monotherapy compared to obinutuzumab/chlorambucil in patients with treatment-naïve CLL, including in patients with high-risk genetic features. Read More ›

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR in Previously Untreated CLL

ASH 2023 - CLL

Results of the UK FLAIR Study indicate that MRD-guided treatment duration of Ibrutinib+ venetoclax significantly improved survival outcomes compared to FCR in untreated chronic lymphocytic leukemia. Read More ›

Updated GLOW Study Results of First-Line Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab

ASH 2023 - CLL

Longer follow-up data of the GLOW study indicate that fixed-duration ibrutinib + venetoclax shows sustained PFS superiority versus chemoimmunotherapy in patients with previously untreated CLL. Read More ›

High Response Rates to Ibrutinib Retreatment After Relapsing with First-Line Fixed Duration Ibrutinib + Venetoclax in CLL/SLL

ASH 2023 - CLL

Updated results of the CAPTIVATE study show promising efficacy with ibrutinib-based retreatment in patients progressing on a first-line, fixed duration ibrutinib + venetoclax regimen. Read More ›

Extended Follow-up of TRANSCEND CLL 004 Trial of Lisocabtagene Maraleucel in R/R CLL/SLL

ASH 2023 - CLL

Longer follow-up data of the TRANSCEND CLL 004 trial indicated that lisocabtagene maraleucel continued to demonstrate durable CR/CRi and high uMRD rates in patients with heavily pretreated, high-risk R/R CLL/SLL; no new safety signals emerged. Read More ›

American Society of Hematology (ASH)

Page 1 of 44